<DOC>
	<DOCNO>NCT01377922</DOCNO>
	<brief_summary>A Phase 3 study evaluate efficacy safety Amifampridine Phosphate patient Lambert-Eaton Myasthenic Syndrome ( LEMS ) .</brief_summary>
	<brief_title>A Phase 3 Study Amifampridine Phosphate Patients With Lambert Eaton Myasthenic Syndrome ( LEMS )</brief_title>
	<detailed_description>This multicenter , double-blind , placebo-controlled , randomize ( 1:1 ) discontinuation study 4 part study design evaluate efficacy safety multiple dose administration amifampridine phosphate patient LEMS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<mesh_term>3,4-diaminopyridine</mesh_term>
	<criteria>Individuals eligible participate study must meet follow inclusion criterion : â‰¥18 year age Confirmed diagnosis LEMS Normal respiratory function Normal swallow function If receive peripherally act cholinesterase inhibitor stable dose require least 7 day prior Screening . If receive oral immunosuppressant stable dose require least 90 day prior Screening . Negative pregnancy test female childbearing potential If sexually active , willing use 2 acceptable method contraception Willing perform study procedure physically possible . Willing able provide write informed consent nature study explain prior start researchrelated procedure . Individuals meet follow exclusion criterion eligible participate study : History epilepsy seizure . Known active brain metastasis . Use Fampridine ( 4aminopyridine ) , form 3,4diaminopyridine IP provide , amifampridine base Firdapse , study . Use medication know lower epileptic threshold within 7 day 5 halflives . Use medication inhibit neuromuscular junction function within 7 day 5 halflives . Use IVIG , plasmapheresis ( plasma exchange ) , immunoadsorption within 90 day Use guanidine hydrochloride within 7 day Use rituximab within 12 month History drug allergy pyridinecontaining substance amifampridine phosphate excipient ( ) . Use investigational productwithin 30 day Treatment concomitant medication prolongs QT/QTc interval within 7 day 5 halflives . Treatment sultopride ( 4aminoN [ ( 1ethylpyrrolidin2yl ) methyl ] 5ethylsulfonyl2methoxybenzamide ) within 7 day . An abnormal electrocardiogram ( ECG ) . Documented history arrhythmia . History additional risk factor torsade de pointes . Breastfeeding pregnant planning become pregnant ( self partner ) time study . Likely expected require treatment cancer within 3 month ( 90 day ) enter . History severe renal impairment evidence severe renal impairment Any condition place patient high risk poor treatment compliance complete study . History uncontrolled asthma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>